Neuro-Oncology Neuro-Oncology, Oxford University Press (OUP), 2021, 23 (9), pp.1547-1559. ⟨10.1093/neuonc/noab088⟩ Neuro-Oncology, 23(9), 1547-1559. Oxford University Press Neuro-oncology, Vol. xx, no.xx, p. xx (2021) Neuro-Oncology, 2021, 23 (9), pp.1547-1559. ⟨10.1093/neuonc/noab088⟩ Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual) Universidade de São Paulo (USP) instacron:USP Neuro-oncology, 23(9), 1547-1559. Oxford University Press
Clinical Cancer Research, 28(12), 2527-2535. American Association for Cancer Research Inc. Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, no.12, p. 2527-2535 (2022) Clin Cancer Res Tesileanu, C M S, Sanson, M, Wick, W, Brandes, A A, Clement, P M, Erridge, S C, Vogelbaum, M A, Nowak, A K, Baurain, J-F, Mason, W P, Wheeler, H, Chinot, O L, Gill, S, Griffin, M, Rogers, L, Taal, W, Rudà, R, Weller, M, McBain, C, van Linde, M E, Aldape, K, Jenkins, R B, Kros, J M, Wesseling, P, von Deimling, A, Hoogstrate, Y, de Heer, I, Atmodimedjo, P N, Dubbink, H J, Brouwer, R W W, van IJcken, W F J, Cheung, K J, Golfinopoulos, V, Baumert, B G, Gorlia, T, French, P J & van den Bent, M J 2022, ' Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype : Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial ', Clinical Cancer Research, vol. 28, no. 12, pp. 2527-2535 . https://doi.org/10.1158/1078-0432.CCR-21-4283 Clinical Cancer Research Clinical Cancer Research, 2022, 28 (12), pp.2527-2535. ⟨10.1158/1078-0432.CCR-21-4283⟩
Acta Neuropathologica, 141(6), 945-957. SPRINGER Acta Neuropathologica, 141(6), 945-957. Springer, Cham Acta Neuropathologica Acta Neuropathologica, 2021, 141 (6), pp.945-957. ⟨10.1007/s00401-021-02291-6⟩ Acta Neuropathologica, 141, 6, pp. 945-957 Acta Neuropathologica, 141(6), 945-957. Springer Verlag Acta Neuropathologica, Springer Verlag, 2021, 141 (6), pp.945-957. ⟨10.1007/s00401-021-02291-6⟩ Tesileanu, C M S, Vallentgoed, W R, Sanson, M, Taal, W, Clement, P M, Wick, W, Brandes, A A, Baurain, J F, Chinot, O L, Wheeler, H, Gill, S, Griffin, M, Rogers, L, Rudà, R, Weller, M, McBain, C, Reijneveld, J, Enting, R H, Caparrotti, F, Lesimple, T, Clenton, S, Gijtenbeek, A, Lim, E, de Vos, F, Mulholland, P J, Taphoorn, M J B, de Heer, I, Hoogstrate, Y, de Wit, M, Boggiani, L, Venneker, S, Oosting, J, Bovée, J V M G, Erridge, S, Vogelbaum, M A, Nowak, A K, Mason, W P, Kros, J M, Wesseling, P, Aldape, K, Jenkins, R B, Dubbink, H J, Baumert, B, Golfinopoulos, V, Gorlia, T, van den Bent, M & French, P J 2021, ' Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations ', Acta Neuropathologica, vol. 141, no. 6, pp. 945-957 . https://doi.org/10.1007/s00401-021-02291-6 Acta Neuropathologica, 141, 945-957 Acta neuropathologica, Vol. xx, no.xx, p. xx (2021) Acta Neuropathologica, 141(6), 945-957. Springer-Verlag
Lancet oncology, 22(6), 813-823. Elsevier Science van den Bent, M J, Tesileanu, C M S, Wick, W, Sanson, M, Brandes, A A, Clement, P M, Erridge, S, Vogelbaum, M A, Nowak, A K, Baurain, J F, Mason, W P, Wheeler, H, Chinot, O L, Gill, S, Griffin, M, Rogers, L, Taal, W, Rudà, R, Weller, M, McBain, C, Reijneveld, J, Enting, R H, Caparrotti, F, Lesimple, T, Clenton, S, Gijtenbeek, A, Lim, E, Herrlinger, U, Hau, P, Dhermain, F, de Heer, I, Aldape, K, Jenkins, R B, Dubbink, H J, Kros, J M, Wesseling, P, Nuyens, S, Golfinopoulos, V, Gorlia, T, French, P & Baumert, B G 2021, ' Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study ', The Lancet Oncology, vol. 22, no. 6, pp. 813-823 . https://doi.org/10.1016/S1470-2045(21)00090-5 Lancet Oncology Lancet Oncology, 2021, 22 (6), pp.813-823. ⟨10.1016/S1470-2045(21)00090-5⟩ The Lancet Oncology, 22(6), 813-823. Lancet Publishing Group The Lancet Oncology, 22(6), 813-823. ELSEVIER SCIENCE INC Lancet Oncology, Elsevier, 2021, 22 (6), pp.813-823. ⟨10.1016/S1470-2045(21)00090-5⟩ Lancet Oncology, 22, 6, pp. 813-823 Lancet Oncology, 22, 813-823
The Lancet, 390(10103), 1645-1653. Elsevier Limited The Lancet, 390(10103), 1645-1653. ELSEVIER SCIENCE INC van den Bent, M J, Baumert, B, Erridge, S C, Vogelbaum, M A, Nowak, A K, Sanson, M, Brandes, A A, Clement, P M, Baurain, J F, Mason, W P, Wheeler, H, Chinot, O L, Gill, S, Griffin, M, Brachman, D G, Taal, W, Rudà, R, Weller, M, McBain, C, Reijneveld, J, Enting, R H, Weber, D C, Lesimple, T, Clenton, S, Gijtenbeek, A, Pascoe, S, Herrlinger, U, Hau, P, Dhermain, F, van Heuvel, I, Stupp, R, Aldape, K, Jenkins, R B, Dubbink, H J, Dinjens, W N M, Wesseling, P, Nuyens, S, Golfinopoulos, V, Gorlia, T, Wick, W & Kros, J M 2017, ' Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma : A phase 3, randomised, open-label intergroup study ', The Lancet, vol. 390, no. 10103, pp. 1645-1653 . https://doi.org/10.1016/S0140-6736(17)31442-3 Lancet, 390(10103), 1645-1653. Elsevier Limited The Lancet (London), 390, 1645-1653 Lancet (UK), 390(10103), 1645-1653. Elsevier Ltd. Lancet, 390(10103), 1645-1653. Elsevier Science The Lancet (London), 390, 10103, pp. 1645-1653